[ad_1] Alexey Krukovsky | Istock | Getty Images Viking Therapeutics shares closed more than 15% higher on Tuesday after the company said its experimental weight loss pill showed positive results in a small study and will enter the next stage of development later this year. The study results add to the excitement around the drugmaker’s…
[ad_1] 3D Illustration of a human liver organ. magicmine | iStock | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment…
[ad_1] Cr | Istock | Getty Images Biotech company Viking Therapeutics has emerged as a strong potential entrant — or takeover target — in the budding weight loss drug market. Viking is just one of several companies racing to join the growing space. Some analysts say the market could be worth $100 billion by the…
[ad_1] Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) Inflation relief: The stock market…
[ad_1] Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Wednesday’s key moments. 1. U.S. stocks were trending lower as investors awaited important inflation data and mulled over more quarterly earnings. January’s PCE price index – the Federal Reserve’s preferred measure of…
[ad_1] Anti-obesity drugmakers Novo Nordisk and Eli Lilly have a huge lead on their competition, but given the vast and valuable market, rivals are still eager to join the race. Bank of America analyst Geoff Meacham has been very bullish about the opportunity, which he calls “unprecedented” given the prevalence of obesity and the huge…
[ad_1] Cr | Istock | Getty Images Shares of Viking Therapeutics soared more than 90% on Tuesday after the company’s experimental weight loss drug showed promising initial results in a mid-stage trial. Viking Therapeutics is one of several small obesity drugmakers hoping to enter the budding weight loss drug industry, which analysts say could grow…
[ad_1] Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity. Michael Siluk | UCG | Getty Images Drugmakers have been scrambling to join a two-horse race to lead the market for popular weight loss drugs, which…
[ad_1] Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to themselves. But given the potential size of this opportunity, which some have put at more than $100 billion by 2030 , other pharmaceuticals companies…
[ad_1] Novo Nordisk and Eli Lilly reign over the anti-obesity drug market, and don’t expect this duopoly to end soon, analysts say. But other companies — both big and small — are hoping to grab a piece of this lucrative market. In a research note, Piper Sandler analyst Yasmeen Rahimi said the firm is tracking…
